Q-omics provides the consensus-scored ZNF598 profile across patient tissues and cancer cell-line models. ZNF598 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF598 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, ZNF598 RNA expression shows 19,423 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where ZNF598 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF598 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF598 survival associations across molecular data types. ZNF598 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF598 RNA expression–survival associations across cancer types. High ZNF598 expression shows unfavorable associations in KIRC, KIRP, ACC, LUAD, LGG and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF598 RNA expression.
This table summarizes ZNF598 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF598. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF598 shows higher tumor expression in COAD, HNSC, KIRP, KIRC, LUAD and LIHC. The COAD box plot shows higher ZNF598 RNA expression in tumor versus normal tissue (log2 FC = +1.560, t-test p < 0.001).
This table shows molecular features associated with ZNF598 in patient tissues and cancer cell lines. In patient samples, ZNF598 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF598 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
